Benjamin William Schlichtmann

Benjamin William Schlichtmann

Auto-generated profile, based on publicly available information

Benjamin William Schlichtmann

Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2018 in Biomedical Materials
Verified
Journal Article
Closed access
PDF file
AMAdam S Mullis
Adam S Mullis
BSBenjamin William Schlichtmann
Benjamin William Schlichtmann
BNBalaji Narasimhan
Balaji Narasimhan
RCRebecca Cademartiri
Rebecca Cademartiri
SMSurya K. Mallapragada
Surya K. Mallapragada
Neurodegenerative diseases are a debilitating set of conditions that affect a significant fraction of the world’s population, and this fraction is expected to increase as the population ages. Many therapeutic strategies have been explored to treat the pathological mechanisms of neurodegenerative diseases, but multiple sequential hurdles to central nervous system (CNS) delivery, including the blood–brain barrier (BBB), diseased neuronal membranes, and the organelle barrier, make drug delivery challenging and necessitate the use of innovative strategies to target and cross each barrier. Advances in drug delivery technology have the potential to improve the standard of treatment for neurodegenerative diseases by enhancing local drug concentration at the pathologically relevant cells and organelles. Furthermore, ligand-cascading nano-delivery devices could address these issues by sequentially presenting targeting ligands for crossing each of the aforementioned hurdles. In this review, we provide an overview of ligand technologies that enable BBB transcytosis, localization to or internalization in diseased neuronal cells, and localization at the organelle of interest. We summarize recent strategies for sequentially presenting pertinent ligands at each hurdle to CNS delivery. These ligand-cascade strategies will enable rational design of nano-delivery devices for multiscale targeting of anti-neurodegenerative therapeutics.

16 November 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
BSBenjamin W. Schlichtmann
Benjamin W. Schlichtmann
NKNaveen Kondru
Naveen Kondru
MHMonica M. Hepker
Monica M. Hepker
AKAnumantha G. Kanthasamy
Anumantha G. Kanthasamy
VAVellareddy Anantharam
Vellareddy Anantharam
BNBalaji Narasimhan
Balaji Narasimhan

5 February 2021 in Current Opinion in Chemical Engineering
Verified
Journal Article
Closed access
BSBenjamin W Schlichtmann
Benjamin W Schlichtmann
MHMonica Hepker
Monica Hepker
BPBharathi N Palanisamy
Bharathi N Palanisamy
MJManohar John
Manohar John
VAVellareddy Anantharam
Vellareddy Anantharam
SMSurya K. Mallapragada
Surya K. Mallapragada